IBA has developed a new particle therapy QA solution to enhance patient-specific quality assurance. This technology helps to enhance particle therapy QA processes within modern oncology care. Furthermore, it helps to enhance the precision of treatment delivery. The company’s solution, myQA MatriXXAir, comes with AI capabilities to enhance the solution’s performance. This solution helps to verify the dose within proton and ion therapy. Moreover, it helps to enhance efficiency within the QA process. This helps to deliver quality treatment to patients.
Advancing Precision and Safety in Proton and Ion Therapy
IBA is also continuing its innovations in particle therapy QA technology. Therefore, the company is committed to enhancing safety and efficiency in radiation therapy. The solution is intended to address the needs of advanced oncology facilities. Hence, healthcare organizations can provide more precise treatments. In addition, the system provides integration capabilities with existing therapy systems. It provides real-time data insights, which help in decision-making. Consequently, healthcare organizations can increase the precision and safety of treatments. Overall, the launch of the solution emphasizes IBA’s position as a leader in oncology technology. It also emphasizes its commitment to advancing proton and ion therapy and patient-specific QA.
Commenting on the solution, Dr. Loïc Grevillot, Deputy Head of Medical Physics at the MedAustron Ion Therapy Center, stated: “We have been pleased to test the latest MatriXX detector from IBA Dosimetry, which offers a user-friendly interface and, most importantly for our needs, compatibility with carbon ion beams. The detector has demonstrated robust performance in dose evaluation and shows potential for clinical implementation in carbon ion therapy beam delivery, QA, and PSQA workflows.”
Jean-Marc Bothy, President of IBA Dosimetry, added: “We are proud to offer products that significantly enhance safety in patient plan deliveries in proton therapy. It’s exciting to see a QA solution designed specifically for particle therapy. MatriXX AiR builds on the strengths of our trusted MatriXX PT and ONE, bringing a new level of precision, speed, and wireless flexibility. We’ve worked closely with clinical teams, and this evolution reflects their need for effective QA that keeps pace with the future of treatment modalities. With this launch, we further strengthen our leadership in quality assurance for particle‑beam therapies.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: GlobeNewswire.com
